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ABSTRACT 
Background: Venlafaxine is a serotonin noradrenaline reuptake inhibitor used to treat major 
depressive episodes and anxiety disorders. The primary aim of this study was to investigate 
spontaneous abortion risks following gestational exposure.  
Methods: This prospective observational comparative cohort study utilised data collected by the UK 
Teratology Information Service (UKTIS) between 1995 and 2018. The study sample included 281 
venlafaxine exposed pregnancies matched to antidepressant unexposed (n=1,405) and SSRI exposed 
(n=843) comparator groups.  
Results: After correction for variation in competing outcome rates and the stage of pregnancy at 
reporting, no statistically significant differences in the hazard of spontaneous abortion was observed 
following gestational venlafaxine use compared with either antidepressant unexposed (HR 1.28, 
95%CI; 0.850 to 1.94) or SSRI exposed (HR 1.03, 95%CI; 0.681 to 1.57) pregnancies.  
Conclusions: No conclusive evidence  is provided from this study that venlafaxine increases the risk 
of adverse pregnancy or fetal outcomes. 
  
HIGHLIGHTS 
• The primary aim of this study was to investigate spontaneous abortion risks following 
gestational venlafaxine use 
• No statistically significant differences in the hazard of spontaneous abortion was 
observed following gestational venlafaxine use compared with either antidepressant 
unexposed (HR 1.28, 95%CI; 0.850 to 1.94) or SSRI exposed (HR 1.03, 95%CI; 0.681 to 
1.57) pregnancies 
• Secondary aims were to investigate congenital malformation and other adverse 
pregnancy outcome risks 
• The overall rate of major congenital malformation among the venlafaxine-exposed 
group (1.42%), was not significantly different from the antidepressant-unexposed 
(1.36%) and SSRI-exposed (1.67%) comparator groups 
• No statistically significant differences in preterm birth or fetal growth parameters were 
observed 
• The findings of this study therefore provide no conclusive evidence that venlafaxine is a 
major human teratogen or fetotoxic agent 
  
1. INTRODUCTION 
Maternal depression is common during pregnancy, with published estimates ranging from 4 to 
20%.[1] Consequently gestational antidepressant use is frequent and has increased over recent 
decades in Europe[2] and the United States.[3] Adequate treatment is important becausepoorly 
controlled gestational depression may increase the risk of adverse maternal[4, 5] fetal,[6] and 
childhood developmental outcomes.[7, 8] It is therefore essential that adequate pregnancy 
pharmacovigilance data are available to allow informed discussions about the safety of gestational 
medication use between patients and health professionals. 
Venlafaxine is a serotonin noradrenaline reuptake inhibitor (SNRI) licensed for the treatment and 
prevention of major depressive episodes, the treatment of generalised and social anxiety disorder, 
and treatment of panic disorder with or without agoraphobia.[9]  
There are considerable human pregnancy exposure data available, which together does not provide 
evidence that venlafaxine increases the overall rate of congenital malformation.[10-15] However, less 
data are available concerning risks of specific malformations and outcomes such as spontaneous 
abortion,[16-18] intrauterine fetal death/stillbirth,[19] preterm delivery[16] and low birth weight.[16] The 
primary aim of this study was to increase the amount of published data available concerning the risk 
of spontaneous abortion following venlafaxine exposure in pregnancy. Secondary aims were to 
investigate intrauterine fetal death/stillbirth, preterm delivery, fetal growth restriction and 
congenital malformation risks. 
2. MATERIALS AND METHODS 
2.1 Study design, setting and data collection procedures 
This study utilised a prospective observational comparative cohort design to analyse teratogen 
surveillance data collected by the UK Teratology Information Service (UKTIS) using standardised 
procedures. In brief, UK-based healthcare professionals are encouraged to contact UKTIS to discuss 
the potential fetal effects of maternal environmental exposures (medicines/occupational chemicals 
etc.) during pregnancy. Upon contact with the service, relevant clinical, obstetric and demographic 
patient information is collected from the health professional to allow accurate fetal risk assessment. 
Subsequently, all enquiries which involve maternal exposures in pregnancy are included in the 
prospective surveillance system. This system utilises postal questionnaires sent shortly after the 
estimated date of delivery (EDD) to collect pregnancy and fetal outcome data from the healthcare 
professional who originally contacted the service. 
2.2 Study sample 
This study sample consists of non-duplicate pregnancy/fetal outcomes collected by the service 
following reports of maternal exposures between September 1995 and August 2018. All pregnancies 
where maternal age details were unavailable, multiple pregnancies (twins/triplets), or where 
maternal poisonings, overdoses or exposure to known or suspected human teratogens/fetotoxic 
agents (including any retinoid, cytotoxic or antiepileptic medication, lithium, methotrexate, 
mycophenolate mofetil, thalidomide, warfarin or coumarin derivatives) was reported (with the 
exception of alcohol and tobacco) were excluded.  
 The exposed study group included pregnancies in which mothers had used venlafaxine at any stage 
of pregnancy. This was compared with two SNRI unexposed comparator groups matched to the 
venlafaxine exposed pregnancies by both calendar year and and maternal age (each ±2 years) at 
UKTIS referral. To provide standard reference outcome rates from the UKTIS surveillance system, the 
primary matched comparator group consisted of pregnancies unexposed to any antidepressant 
medications (matching ratio 5:1). These pregnancies were typically reported to UKTIS to discuss 
exposure to agents not known to be teratogenic such as vitamin supplements, dental x-rays mild and 
simple analgesics such as paracetamol or acetylsalicylic acid. To control by design for the potential 
impact of confounding variables common to women with gestational depression, a disease-matched 
comparator group was included which consisted of matched SSRI antidepressant exposed 
pregnancies (matching ratio 3:1). These disease-matched comparators were selected by SSRI 
exposure status and the health professional  reported exposure indication only. No information was 
available to UKTIS regarding disease type or severity. 
2.3 Definitions 
Standard definitions for the exposure and outcome variables were used for this study, further details 
are provided in Table 1 of the Supplementary Appendix. 
2.4 Statistical analysis 
Normality of continuous variables was assessed using the Shapiro-Wilks test. Continuous variables 
which were not considered normally distributed were described using the median and interquartile 
range and compared using the Mann-Whitney-Wilcoxon test. Categorical variables were expressed 
as counts and percentages, and were compared using Chi-squared or Fisher’s exact tests when Chi-
squared assumptions were not met. Rates of pregnancy and fetal outcomes were compared 
between exposed and control groups using exact methods to generate unadjusted crude odds ratios 
(OR) and their 95% confidence intervals. Additional  adjusted analyses were conducted using 
binomial logistic regression to assess the impact of co-variates (tobacco, alcohol, recreational drug 
and folic acid use) on adverse pregnancy outcome risk estimates. In instances where these 
exposures were not confirmed by the reporting healthcare professional, non-exposure was 
assumed.  
Crude spontaneous abortion rates were calculated for pregnancies reported to UKTIS prior to 24 
weeks which did not result in elective termination. For the venlafaxine and SSRI exposed 
pregnancies the respective exposures must also have been prior to 24 weeks. Crude intrauterine 
fetal death/stillbirth rates were calculated using pregnancies which resulted in either an intrauterine 
fetal death/stillbirth or live birth as the rate denominator. Crude congenital malformation rates were 
calculated for all reported pregnancies after excluding those which resulted in congenital 
malformations considered as genetic/cytogenetic in aetiology. 
To account for variation in both the stage of pregnancy at reporting to UKTIS and rates of competing 
risks, event-history analysis methods[20] were used to compute the cumulative incidence of 
spontaneous abortion and compare these between the exposed and comparator groups. This 
analysis was conducted using a restricted dataset of pregnancies where the maternal stage of 
pregnancy was reported at the initial time of reporting to UKTIS and when the pregnancy ended, and 
provided venlafaxine/SSRI use occurred during the risk period (<24 weeks gestation). Cause-specific 
cumulative incidences and their 95% confidence limits were plotted and compared using a Z-test.[20] 
Time-dependent Cox proportional hazards models were also constructed to compare the hazard of 
spontaneous abortion between the exposed and comparator groups whilst accounting for the 
impact of competing risks and left-truncation. Variables entered into the unadjusted models 
included the stage of pregnancy (in weeks post-LMP) at reporting to UKTIS and separately at 
pregnancy outcome, the venlafaxine exposure status, and the pregnancy outcome (elective 
termination, spontaneous abortion, stillbirth or live birth). Proportional hazards assumptions were 
tested using Schoenfeld residuals and a chi-squared test to identify non-proportionality (P<0.05). 
The impact of co-variates (history of spontaneous abortion and exposure to tobacco, alcohol, 
recreational drugs and folic acid) were also estimated by adding these details to the Cox 
proportional hazards models. 
All data manipulations and statistical analyses were conducted in R version 3.4.1.[21] Matching of 
venlafaxine and comparator pregnancies was undertaken using the “Optmatch”[22] package in R. 
Logistic regression analyses were conducted using the “aod”[23] add-on packages. Event-history 
analysis methods and the Cox proportional hazards models were performed using the “ETM”[24] and 
“Survival”[25] add-on packages. No multiple comparison corrections were performed, and a P-value 
of <0.05 was used to indicate statistical significance in all tests. 
2.5 Regulatory and ethical considerations 
Regulatory approval for the national surveillance conducted by UKTIS is provided through section 
251 of the NHS Act 2006. The analysis of routine anonymised surveillance data collected through this 
mechanism did not require separate approval by a UK Research Ethics Committee. 
3. RESULTS 
3.1 Study sample 
A total of 7,897 pregnancies did not meet any of the study exclusion criteria, from  which 281 
venlafaxine exposed pregnancies were identified and matched to 1,405 antidepressant unexposed 
pregnancies and 843 SSRI exposed pregnancies.  
Gestational venlafaxine exposure occurred in at least the first trimester for the majority of the 
venlafaxine exposed study group (n=270/281, 96.1%), with treatment being initiated before the 24th 
gestational week of pregnancy in all but four. Details relating to the exact gestational age (in weeks 
post-LMP) when venlafaxine treatment was started were available for 196 pregnancies. Of these, 
the majority were exposed from prior to conception (n=167/196, 85.2%), and for exposures where 
venlafaxine was commenced during pregnancy (n=29), therapy was started at a median of 6 weeks 
(IQR: 5 to 10 weeks, range 3 to 21). A total of 174 pregnancies had information relating to the stage 
of pregnancy when venlafaxine was both commenced and ended, and these data describe a median 
therapeutic exposure period spanning 7 gestational weeks (IQR: 5 to 11 weeks, range 1 to 40) 
Concomitant psychiatric medication use was common among the venlafaxine exposed pregnancies 
with co-exposure to other antidepressants, antipsychotics, benzodiazepines or hypnotic 
benzodiazepine receptor antagonists being reported for 94 of 281 women in this group (33.5%). In 
the SSRI exposed group comparator group, 79 women used more than one SSRI, with the majority 
were exposed to fluoxetine (33.0%), citalopram (31.2%) or sertraline (21.4%), with fewer exposed to 
paroxetine (16.6%), escitalopram (3.08%) and fluvoxamine (0.237%). 
3.2 Maternal demographics 
A comparison of the maternal demographics among the three study groups is provided in Table 1. 
The matching process limited any statistically significant differences between the exposed and 
comparator groups for both calendar year of pregnancy and maternal age. In comparison with the 
antidepressant unexposed pregnancies those exposed to venlafaxine were reported to UKTIS at a 
significantly earlier stage of pregnancy, the median BMI was significantly higher (although there was 
no overall significant difference when maternal BMI was compared categorically), and a significantly 
higher proportion reported gestational tobacco use. In contrast, comparisons with the SSRI exposed 
controls did not identify any statistically significant differences. 
 
 
 
 
 
 
 
Table 1: Comparison of maternal demographics between the venlafaxine, antidepressant unexposed 
and SSRI exposed study groups 
 Venlafaxine 
Antidepressant 
Unexposed P-Value SSRI P-Value 
      
Total Participants - n 281 1,405 - 843 - 
      
Year of TIS Reporting - data available n 
(% total)* 
281 (100) 1,405 (100) - 843 (100) - 
Enrolment year - median (IQR) 2006 (2001 to 
2012) 
2007 (2001 to 
2012) 
0.907 2007 (2002 to 
2012) 
0.856 
      
Maternal Age at TIS Reporting - data 
available n (% total)* 
281 (100) 1,405 (100) - 843 (100) - 
Age - median (IQR) 31 (28 to 35) 31 (28 to 35) 0.974 31 (27 to 35) 0.936 
<20 or ≥35 - n (%) 85 (30.2) 423 (30.1) 1.00 247 (28.1) 0.821 
      
GA at TIS Reporting - data available n 
(% total) 
249 (88.6) 1,281 (91.2) - 750 (89.0) - 
Weeks post-LMP - median (IQR) 7 (5 to 11) 10 (6 to 20) <0.001 8 (5 to 15) 0.0722 
      
Ethnicity - data available n (% total) 76 (27.1) 350 (24.9) - 200 (23.7) - 
White ethnicity - n (%) 71 (93.4) 291 (83.1) 0.0213‡ 181 (90.5) 0.633 
      
BMI - data available n (% total) 56 (19.9) 268 (19.1) - 147 (17.4) - 
BMI Score (kg/m2) - median (IQR) 28.0 (23.1 to 
32.8) 
25.0 (22.2 to 
29.0) 
0.0334 25.8 (22.3 to 
32.3) 
0.309 
Underweight (< 18.5 kg/m2) - n (%) 3 (5.36) 8 (2.99) 
0.0645‡ 
4 (2.72) 
0.316‡ 
Healthy (18.5 to 24.9 kg/m2) - n (%) 18 (32.1) 125 (46.6) 66 (44.9) 
Overweight (25.0 to 29.9 kg/m2) - n (%) 14 (25.0) 73(27.2) 29 (19.7) 
Obese (≥ 30 kg/m2) - n (%) 21 (37.5) 62 (23.1) 48 (32.7) 
      
Gravidity - data available n (% total) 236 (84.0) 1,119 (79.6) - 698 (82.8) - 
Multi-gravida - n (%) 163 (69.1) 727 (65.0) 0.259 482 (69.1) 1.00 
History of SA - n (% multi-gravida) 26 (16.0) 105 (14.4) 0.712 53 (11.0) 0.429 
      
Tobacco Use - data available n (% 
total) 
100 (35.6) 509 (36.2) - 295 (35.0) - 
Use in pregnancy - n (%) 51 (51.0) 197 (38.7) 0.0295 157 (53.2) 0.788 
      
Alcohol Use - data available n (% total) 62 (22.1) 246 (17.5) - 148 (17.6) - 
Use in pregnancy - n (%) 22 (35.5) 91 (37.0) 0.942 59 (40.0) 0.660 
      
Recreational Drug Use - data available 
n (% total) 
74 (26.3) 339 (24.1) - 198 (23.5) - 
Use in pregnancy - n (%) 11 (14.9) 49 (14.5) 1.00 29 (14.7) 1.00 
      
Folate Use - data available n (% total) 78 (27.8) 438 (31.2) - 246 (29.2) - 
Use in pregnancy - n (%) 73 (93.6) 415 (94.8) 0.595‡ 228 (92.7) 1.00‡ 
      
Key: SSRI= selective serotonin reuptake inhibitors, TIS= teratology information service, IQR= 
interquartile range, GA= gestational age, BMI= body mass index, * indicates matched demographics, 
‡ indicates that the P-value was calculated using Fisher’s exact test 
 
3.3 Pregnancy and fetal outcomes 
Comparisons of the crude pregnancy/fetal outcome rates are provided in Table 2. There were 
limited differences in adverse pregnancy/fetal outcomes among the three groups. In comparison 
with the antidepressant unexposed controls, the crude rate of live birth was significantly decreased 
following venlafaxine exposure; an observation which appeared mainly driven by a statistically 
significant increase in crude spontaneous abortion rate. However, when comparisons were made 
with the disease-matched SSRI-exposed group, no statistically significant differences were observed 
for any of the outcomes analysed. 
Table 2: Comparison of crude pregnancy and fetal outcome rates between the venlafaxine, antidepressant unexposed and SSRI exposed study groups 
 Venlafaxine 
Antidepressant 
Unexposed P-Value OR (95% CI) SSRI P-Value OR (95% CI) 
Total Pregnancies 281 1,405 - - 843 - - 
ETOP - n (%) 21 (7.47) 103 (7.33) 1.00 1.02 (0.595 to 1.68) 71 (8.42) 0.706 0.878 (0.502 to 1.48) 
SA - n (%*) 46 (21.0) 140 (14.5) 0.0225 1.57 (1.06 to 2.30) 114 (20.1) 0.865 1.05 (0.700 to 1.57) 
IUFD/SB - n (%**) 3 (1.40) 12 (1.03) 0.717‡ 1.36 (0.245 to 5.11) 7 (1.06) 0.714‡ 1.32 (0.219 to 5.85) 
LB - n (%) 211 (75.1) 1150 (81.9) 0.0111 0.669 (0.490 to 0.919) 651 (77.2) 0.515 0.889 (0.643 to 1.24) 
        
GAD recorded 198 1,081 - - 614 - - 
PTD - n (%) 33 (16.7) 125 (11.6) 0.0589 1.53 (0.974 to 2.35) 81 (13.2) 0.269 1.32 (0.819 to 2.08) 
        
Infants with GAD & BW recorded 140 815 - - 460 - - 
Term LBW - n (%) 4 (2.86) 29 (3.56) 0.807‡ 0.797 (0.200 to 2.32) 22 (4.78) 0.477‡ 0.586 (0.144 to 1.77) 
SGA - n (%***) 12 (9.02) 65 (9.00) 1.00 1.00 (0.478 to 1.94) 55 (12.6) 0.339 0.691 (0.326 to 1.36) 
        
Genetic Conditions Excluded 281 1,400 - - 838 - - 
Any CM - n (%) 7 (2.49) 47 (3.36) 0.579‡ 0.736 (0.278 to 1.66) 33 (3.94) 0.353‡ 0.623 (0.230 to 1.45) 
Major CM - n (%) 4 (1.42) 19 (1.36) 1.00‡ 1.05 (0.258 to 3.19) 14 (1.67) 1.00‡ 0.850 (0.202 to 2.74) 
Minor CM - n (%) 3 (1.07) 28 (2.00) 0.463‡ 0.529 (0.102 to 1.73) 19 (2.27) 0.319‡ 0.465 (0.0876 to 1.60) 
T1 Exposed 270 1,400 - - 716 - - 
Any CM - n (%) 7 (2.59) 47 (3.36) 0.706‡ 0.766 (0.289 to 1.73) 28 (3.90) 0.440‡ 0.654 (0.238 to 1.56) 
Major CM - n (%) 4 (1.48) 19 (1.36) 0.779‡ 1.09 (0.268 to 3.32) 12 (1.68) 1.00‡ 0.882 (0.206 to 2.94) 
Key: OR= odds ratio, CI= confidence interval, SSRI= selective serotonin reuptake inhibitors, ETOP= elective termination of pregnancy, SA= spontaneous 
abortion (*denominator restricted to exclude pregnancies ending in ETOP or reported to UKTIS ≥24 weeks gestational age - venlafaxine n=219, 
antidepressant unexposed n=965 and SSRI n=566), IUFD/SB= intrauterine fetal death or stillbirth (**denominator restricted to exclude pregnancies ending 
in ETOP or SA - venlafaxine n=214, antidepressant unexposed n=1,162 and SSRI n=658), LB= live birth, GAD= gestational age at delivery, PTD= preterm 
delivery, BW= birth weight, LBW= low birth weight, SGA= small for gestational age (***denominator restricted to exclude pregnancies without relevant 
information for calculating the SGA rate - venlafaxine n=133, antidepressant unexposed n=722 and SSRI n=438), CM= congenital malformation, T1= first 
trimester 
‡ indicates that the P-value was calculated using Fisher’s exact test 
3.3.1 Spontaneous abortion risks 
To assess the risk of spontaneous abortion whilst controlling for variation in the stage of pregnancy 
reporting to UKTIS and rates of competing risks, event-history analysis was performed on a 
restricted dataset (venlafaxine n=208, NTE n=912 and SSRI n=550). Crude analysis of this restricted 
dataset produced similar risk estimates to those presented in Table 2 (data presented in 
supplementary table 2), although a lower rate of elective termination was observed following 
venlafaxine exposure in comparison with the antidepressant unexposed group. 
Figure 1 provides plots of the event-history analysis adjusted spontaneous abortion cumulative 
incidences for the venlafaxine exposed pregnancies (24.5, 95% CI; 17.0 to 34.6) in comparison with 
(a) the antidepressant unexposed (20.3, 95% CI; 16.2 to 25.1) and (b) the SSRI exposed comparator 
groups (28.2, 95% CI; 21.4 to 36.7). As demonstrated by the overlapping plots of cumulative 
incidence functions, after adjustment for variation in gestational age at enrolment and competing 
risks no statistically significant differences remained (Z-test P=0.198 and P=0.264 respectively). 
Unadjusted time-dependent Cox proportional hazards models comparing the casue-specific hazard 
of spontaneous abortion between the venlafaxine exposed and a) the antidepressant unexposed (HR 
1.28, 95% CI; 0.85 to 1.94) and (b) the SSRI exposed comparator groups (HR 1.03, 95% CI; 0.681 to 
1.57) also provided no evidence of an association. 
 
Figure 1: Comparison of the cumulative incidence of spontaneous abortion between venlafaxine 
exposed and the (a) antidepressant unexposed (P=0.198) and (b) SSRI exposed study groups 
(P=0.264). 
3.3.2 Congenital malformations 
Seven venlafaxine exposed infants were reported to have congenital malformations, Four infants 
with major malformations including tetralogy of Fallot, fixed bilateral talipes equinovarus, 
hypospadias, and meningoencephalocele diagnosed via ultrasound scan with subsequent elective 
termination, each affecting a single infant exposed in the first trimester. Three minor malformations 
included one infant with unilateral mild talipes equinovarus and a capillary haemangioma, one infant 
with a funnel chest and one male infant with unilateral cryptorchidism. 
Comparisons of the crude malformation rates are provided in Table 2. There were no statistically 
significant differences in major malformation rates following exposure at either any time in 
pregnancy or following exposure in the first trimester only. 
3.3.3 Adjusted analyses 
Adding co-variable estimates to the cause-specific Cox proportional hazards models did not have a 
substantial effect on the risk estimate or the statistical significance for the hazard of  spontaneous 
abortion following venlafaxine exposure in comparison with either the antidepressant unexposed 
(aHR 1.26, 95% CI; 0.829 to 1.91) or SSRI-exposed controls (aHR 1.00, 95% CI; 0.655 to 1.53). 
Similarly, consideration of co-variable estimates did not alter the statistical significance for the risks 
of preterm delivery, term low birth weight, small for gestational age, any or major congenital 
malformation, including with restriction to first trimester exposed pregnancies (Table 3). 
Table 3: Comparison of pregnancy and fetal outcome rates between the venlafaxine, and the 
antidepressant unexposed and SSRI exposed study groups whilst also considering estimates of co-
variables 
 Venlafaxine 
Antidepressant 
Unexposed aOR (95% CI) SSRI aOR (95% CI) 
GAD recorded 198 1081 - 614 - 
PTD - n (%) 33 (16.7) 125 (11.6) 1.51 (0.979 to 2.27) 81 (13.2) 1.32 (0.844 to 2.06) 
      
Term Infants with BW recorded 140 815  460  
Term LBW - n (%) 4 (2.86) 29/ (3.56) 0.794 (0.231 to 2.08) 22/ (4.78) 0.610 (0.175 to 1.64) 
SGA - n (%*) 12 (9.02) 65 (9.00) 1.03 (0.508 to 1.89) 55 (12.6) 0.714 (0.353 1.35) 
      
Genetic Conditions Excluded 281 1400  838  
Any CM - n (%) 7 (2.49) 47 (3.36) 0.711 (0.290 to 1.50) 33 (3.94) 0.641 (0.257 to 1.39) 
Major CM - n (%) 4 (1.42) 19 (1.36) 1.06 (0.305 to 2.87)** 14 (1.67) 0.864 (0.243 to 2.44) 
T1 Exposed 270 1400  716  
Any CM - n (%) 7 (2.59) 47 (3.36) 0.628 (0.238 to 1.38) 28 (3.90) 0.567 (0.209 to 1.30) 
Major CM - n (%) 4 (1.48) 19 (1.36) 1.10 (0.316 to 2.97)** 12 (1.68) 0.893 (0.247 to 2.60) 
Key: aOR= adjusted odds ratio, CI= confidence interval, SSRI= selective serotonin reuptake inhibitors, 
GAD= gestational age at delivery, PTD= preterm delivery, BW= birth weight, LBW= low birth weight, 
SGA= small for gestational age (*denominator further restricted to exclude pregnancies without 
relevant information for calculating the SGA rate - venlafaxine n=133, antidepressant unexposed 
n=722 and SSRI n=438), CM= congenital malformation, T1= first trimester 
Odds ratios adjusted for tobacco, alcohol, recreational drug and folic acid use 
4. DISCUSSION 
Comparisons between the venlafaxine-exposed and the antidepressant unexposed group identified 
a statistically significant increased crude rate of spontaneous abortion, but this was not observed in 
comparison with a disease-matched control group of SSRI exposed pregnancies. Furthermore, event-
history analysis adjustment and inclusion of the data in a time-dependent Cox proportional hazards 
model which both account for variation in gestational age at enrolment and rates of competing risks 
attenuated the statistically significant difference. No statistically significant differences in preterm 
birth or fetal growth parameters were observed. The overall rate of major congenital malformation 
among the venlafaxine-exposed group (1.42%), was not significantly different from the 
antidepressant-unexposed (1.36%) and SSRI-exposed (1.67%) comparator groups. As such, the 
findings of this study provide no conclusive evidence that venlafaxine is a major human teratogen or 
fetotoxic agent. 
4.1 Published evidence 
Controlled studies investigating the risk of adverse pregnancy or fetal outcomes following maternal 
venlafaxine use in human pregnancy consist of eight prospective cohort studies,[10-13, 15-17, 26] four 
case-control studies[18, 27-29] and a systematic review[14] which together report the outcomes of at 
least 4,000 unique exposed pregnancies. None of these studies have identified statistically significant 
increased risks of any congenital malformation overall,[10-16] however, some conflicting results have 
been provided for other adverse pregnancy/fetal outcomes.[17, 18, 27, 29] Two studies suggested 
possible associations with spontaneous abortion,[17, 18] while one did not.[16] Two case-control studies 
which used an overlapping dataset also suggested possible associations with cardiac 
malformation,[27, 29] but other large cohort studies have not replicated these findings.[10, 12, 13, 15] 
Associations with other specific malformations have also been reported in individual studies[10, 27-29] 
including cleft palate,[27, 29] gastroschisis,[27, 29] limb defects,[27] anencephaly,[29] hypospadias,[28] and 
respiratory system defects.[10] 
4.2 Interpretation of study results 
As the results of this prospective comparative cohort study suggest that the differences in crude 
spontaneous abortion rates observed between the venlafaxine exposed and antidepressant 
unexposed study group may have been due to data confounding, and no statistically significant 
increased risks of other adverse pregnancy or fetal outcomes were observed, the findings are 
considered to be largely in keeping with the published literature.  
4.3 Strengths and limitations 
This study represents the first controlled analysis of maternal venlafaxine use using surveillance data 
collected from a UK pregnant population. To limit the impact of inclusion bias, the surveillance data 
included in this study were collected prospectively. Both comparator groups were sourced internally 
using the same data collection procedure as for the venlafaxine exposed study group. This is also the 
largest disease-matched controlled study to investigate congenital malformation risks following 
maternal venlafaxine use in pregnancy. The disease-matched comparator group of SSRI exposed 
pregnancies was included to assess possible confounding by indication. Observations of similar 
adverse pregnancy/fetal risk estimates for the venlafaxine and SSRI exposed groups (see Table 2) 
could be indicative of data confounding, highlighting the importance of a disease-matched control 
group and subsequently allowing more accurate conclusions to be drawn from the results. 
Alternatively however, it is accepted that given the disease-matched control group used in this study 
was not unexposed to medication, these results could have been produced due to similar fetal 
effects of both SSRI and venlafaxine intrauterine exposure. 
The predominant limitation of the UKTIS surveillance method relates to the potential for adverse 
outcome detection heterogeneity. As UKTIS collect outcome information from numerous healthcare 
professionals, responder clinical knowledge and experience is not standardised which could 
theoretically lead to variation in the rate of outcome reporting. Additionally, outcome data are 
requested shortly following the estimated delivery date, but these outcome information may be 
provided up to six months post-delivery. As evidence is available which has shown that a higher 
proportion of infants are diagnosed with congenital malformations by one year of age than at 
birth,[30] non-standardisation of the time at which outcomes are provided may represent an 
additional source of outcome reporting variation.  
In relation to the analysis of the spontaneous abortion data, adequate details regarding the exact 
stage of pregnancy when venlafaxine exposure began and ended was not available for a large 
proportion of the exposed pregnancies. It was therefore not possible to undertake an analysis which 
considered venlafaxine exposure as a time-dependent variable.  
A further important limitation was the small sample size which precluded the ability to detect 
increased risks for some of the adverse pregnancy outcomes analysed. For example, with a major 
congenital malformation rate of 1.36% among the antidepressant unexposed pregnancies (matched 
5:1), the venlafaxine exposed study sample size (n=281) was only sufficient (statistical power 80% 
and alpha 0.05) to detect an approximate 3.4-fold increased risk. As a result some imprecise risk 
estimates were provided. There were also a small number of pregnancies with exposure to 
venlafaxine in monotherapy. The ability to use statistical techniques to adjust risk estimates for 
concomitant exposures and variation in maternal demographics was limited by the large amount of 
missing data present in the UKTIS dataset. As such, it was only possible to add estimates of binary 
co-variables to the statistical models. These included maternal exposure to tobacco, alcohol, 
recreational drugs and folic acid during pregnancy, and were categorised as dichotomous variables 
(exposure yes or no), with absent values interpreted as no exposure. Other more detailed variables, 
such as those relating to body mass index, ethnicity or gravidity, could not be considered. 
Furthermore, the magnitude of the missing data, which exceeded 10% for most variables, precluded 
the reliable use of multiple imputation techniques.[31] Residual data confounding is therefore likely, 
however, restricting the venlafaxine and SSRI exposed groups by excluding all pregnancies where the 
mothers used more than one class of psychiatric medication did not substantially alter the results 
presented in Table 2 (data presented in supplementary table 4).  
5. CONCLUSIONS 
No conclusive evidence of an increased risk of adverse pregnancy or fetal outcomes is provided from 
this study of gestational venlafaxine use. However, further research may be warranted. 
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7. SUPPLEMENTARY TABLES 
Table S1: Exposure and outcome variable definitions 
Variable Definition 
Gestational age Estimated from ultrasound examinations or in weeks post the first day of the last 
menstrual period (LMP) when ultrasound examinations had not been performed 
First trimester First 13 weeks of pregnancy (0 to 90 days post-LMP) 
Spontaneous abortion  Fetal loss up to 24 completed weeks gestation (up to 168 days post-LMP) 
Intrauterine death/stillbirth Fetal loss from 24 weeks onwards (169+ days post-LMP) or peripartum death 
Body mass index (BMI) Calculated as kg/m2, underweight <18.5, normal range 18.5-25, overweight 25-30, 
and obese ≥30 
Preterm delivery Live born infants delivered prior to 37 completed weeks 
Low birth weight Live born infants with a birth weight <2,500g 
Small for gestational age Defined as a live born infant with a birth weight for gestational age which was less 
than the 10th percentile after consideration of the infant sex and maternal parity 
Birth defects Birth defects reported to the service which were not considered to be of genetic 
aetiology were classified as either major or minor as per the EUROCAT classification 
system. Classification was performed by two of the study authors (AG and LMY) 
whilst blind to maternal exposure status. In cases of disagreement, consensus was 
achieved through discussion. 
 
  
Table S2: Comparison of crude outcome rates between the venlafaxine, and the antidepressant 
unexposed and SSRI exposed study groups after restriction to include pregnancies reported to UKTIS 
prior to 24 weeks gestational age where the gestational age at pregnancy outcome was also 
available 
 Venlafaxine 
Antidepressant 
Unexposed OR (95% CI) SSRI OR (95% CI) 
Total Pregnancies 208 912 - 550 - 
ETOP - n (%) 8 (3.85) 40 (4.39) 0.872 (0.347 to 1.93) 29 (5.27) 0.719 (0.279 to 1.65) 
SA - n (%*) 31 (14.9) 83 (9.10) 1.75 (1.08 to 2.77) 77 (14.0) 1.08 (0.661 to 1.72) 
IUFD/SB - n (%**) 3 (1.44) 7 (7.68) 1.89 (0.313 to 8.37) 6 (1.09) 1.33 (0.213 to 6.28) 
LB - n (%) 166 (79.8) 782 (85.8) 0.657 (0.441 to 0.993) 438 (79.6) 1.01 (0.67 to 1.54) 
Key: OR= odds ratio, CI= confidence interval, SSRI= selective serotonin reuptake inhibitors, ETOP= 
elective termination of pregnancy, SA= spontaneous abortion (*denominator restricted to exclude 
pregnancies ending in ETOP reported to UKTIS ≥24 weeks gestational age - venlafaxine n=212, 
antidepressant unexposed n=925 and SSRI n=583), IUFD/SB= intrauterine fetal death or stillbirth 
(**denominator restricted to exclude pregnancies ending in ETOP or SA - venlafaxine n=171, 
antidepressant unexposed n=802 and SSRI n=450), LB= live birth 
 
 
  
Table S3: Comparison of crude pregnancy and fetal outcome rates between the venlafaxine, and the 
antidepressant unexposed and SSRI exposed study groups after exclusion of pregnancies where the 
mothers used more than one class of psychiatric medication 
 Venlafaxine 
Antidepressant 
Unexposed OR (95% CI) SSRI OR (95% CI) 
Total Pregnancies 187 1382 - 674 - 
ETOP - n (%) 15 (8.02) 102 (7.38) 1.09 (0.577 to 1.95) 61 (9.05) 0.877 (0.451 to 1.61) 
SA - n (%*) 36 (23.8) 137 (14.3) 1.59 (1.02 to 2.42) 90 (19.2) 1.11 (0.699 to 1.74) 
IUFD/SB - n (%**) 3 (2.21) 11 (0.962) 2.32 (0.41 to 8.93) 5 (0.956) 2.33 (0.358 to 12.2) 
LB - n (%) 133 (71.1) 1132 (81.9) 0.544 (0.382 to 0.784) 518 (76.9) 0.742 (0.509 to 1.09) 
      
GAD recorded 126 1,063 - 488 - 
PTD - n (%) 20 (15.9) 121 (11.4) 1.47 (0.831 to 2.49) 59 (12.1) 1.37 (0.748 to 2.43) 
      
Term Infants with BW recorded 92 802 - 373 - 
Term LBW - n (%) 2 (2.17) 26 (3.24) 0.664 (0.0751 to 2.72) 14 (3.75) 0.57 (0.0618 to 2.55) 
SGA - n (%***) 7 (8.05) 62 (8.71) 0.917 (0.342 to 2.1) 37 (10.6) 0.267 (1.76 to 0.556) 
      
Genetic Conditions Excluded 187 1,377 - 669 - 
Any CM - n (%) 3 (1.6) 47 (3.41) 0.462 (0.091 to 1.46) 24 (3.59) 0.439 (0.0836 to 1.47) 
Major CM - n (%) 2 (1.07) 19 (1.38) 0.773 (0.0866 to 3.25) 11 (1.64) 0.647 (0.0691 to 3) 
Minor CM - n (%) 1 (0.535) 28 (2.03) 0.259 (0.00631 to 1.59) 13 (1.94) 0.272 (0.00635 to 1.83) 
T1 Exposed 183 1,377 - 583 - 
Any CM - n (%) 3 (1.64) 47 (3.41) 0.472 (0.093 to 1.49) 20 (3.43) 0.47 (0.0883 to 1.61) 
Major CM - n (%) 2 (1.09) 19 (1.38) 0.790 (0.0885 to 3.32) 9 (1.54) 0.705 (0.0735 to 3.45) 
Key: OR= odds ratio, CI= confidence interval, SSRI= selective serotonin reuptake inhibitors, ETOP= 
elective termination of pregnancy, SA= spontaneous abortion (*denominator restricted to exclude 
pregnancies ending in ETOP reported to UKTIS ≥24 weeks gestational age - venlafaxine n=151, 
antidepressant unexposed n=960 and SSRI n=468), IUFD/SB= intrauterine fetal death or stillbirth 
(**denominator restricted to exclude pregnancies ending in ETOP or SA - venlafaxine n=136, 
antidepressant unexposed n=1,143 and SSRI n=523), LB= live birth, GAD= gestational age at delivery, 
PTD= preterm delivery, BW= birth weight, LBW= low birth weight, SGA= small for gestational age 
(***denominator restricted to exclude pregnancies without relevant information for calculating the 
SGA rate - venlafaxine n=87, antidepressant unexposed n=712 and SSRI n=348), CM= congenital 
malformation, T1= first trimester 
 
 
 
 
